Molecular biomarkers in cancer
VK Sarhadi, G Armengol - Biomolecules, 2022 - mdpi.com
Molecular cancer biomarkers are any measurable molecular indicator of risk of cancer,
occurrence of cancer, or patient outcome. They may include germline or somatic genetic …
occurrence of cancer, or patient outcome. They may include germline or somatic genetic …
The Influence of the Microbiome on Immunotherapy for Gastroesophageal Cancer
N Dadgar, V Edlukudige Keshava, MS Raj, PL Wagner - Cancers, 2023 - mdpi.com
Simple Summary This article delves into the mounting impact of the microbiome on
gastroesophageal cancer. Investigating its connection to immunotherapy, this study explores …
gastroesophageal cancer. Investigating its connection to immunotherapy, this study explores …
[HTML][HTML] The level of macrophage migration inhibitory factor is negatively correlated with the efficacy of PD-1 blockade immunotherapy combined with chemotherapy …
L Wu, Y Gao, S Xie, W Ye, Y Uemura, R Zhang… - Translational …, 2023 - Elsevier
Purpose This study aimed to screen biomarkers to predict the efficacy of programmed cell
death 1 (PD-1) blockade immunotherapy combined with chemotherapy as neoadjuvant …
death 1 (PD-1) blockade immunotherapy combined with chemotherapy as neoadjuvant …
POLD4 Promotes Glioma Cell Proliferation and Suppressive Immune Microenvironment: A Pan-Cancer Analysis Integrated with Experimental Validation
C Jiang, F Fan, W Xu, X Jiang - International Journal of Molecular …, 2023 - mdpi.com
POLD4 plays a crucial part in the complex machinery of DNA replication and repair as a vital
component of the DNA polymerase delta complex. In this research, we obtained original …
component of the DNA polymerase delta complex. In this research, we obtained original …
Development and validation of a novel lysosome-related LncRNA signature for predicting prognosis and the immune landscape features in colon cancer
F Li, W Wang, G Lai, S Lan, L Lv, S Wang, X Liu… - Scientific Reports, 2024 - nature.com
Lysosomes are essential components for managing tumor microenvironment and regulating
tumor growth. Moreover, recent studies have also demonstrated that long non-coding RNAs …
tumor growth. Moreover, recent studies have also demonstrated that long non-coding RNAs …
Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational …
N Li, Z Wan, D Lu, R Chen, X Ye - Frontiers in Immunology, 2023 - frontiersin.org
Genetic mutations that render mismatch repair defective may result in microsatellite
instability, which is common in colorectal carcinomas and gastric cancers as well as Lynch …
instability, which is common in colorectal carcinomas and gastric cancers as well as Lynch …
Pancancer Analysis of Revealed TDO2 as a Biomarker of Prognosis and Immunotherapy
J Cui, Y Tian, T Liu, X Lin, L Li, Z Li, L Shen - Disease Markers, 2022 - Wiley Online Library
Background. Tryptophan 2, 3‐dioxygenase (TDO) encoded by TDO2, a rate‐limiting enzyme
in the kynurenine pathway, catabolizes tryptophan to kynurenine, evades immune …
in the kynurenine pathway, catabolizes tryptophan to kynurenine, evades immune …
Elevated THBS3 predicts poor overall survival for clear cell renal cell carcinoma and identifies LncRNA/RBP/THBS3 mRNA networks
G Wang, F Qu, J Zhou, B Zhu, Y Gao - Cell Cycle, 2023 - Taylor & Francis
This study was used to assess THBS3's overall survival (OS) prognostic values in clear cell
renal cell carcinoma (ccRCC) as well as to determine the LncRNA/RNA binding protein …
renal cell carcinoma (ccRCC) as well as to determine the LncRNA/RNA binding protein …
From tumor microenvironment to emerging biomarkers: the reshaping of the esophageal squamous cell carcinoma tumor microenvironment by neoadjuvant …
Z Qiu, Z Li, X Liu, R Zhang, Y Li, C Gao, X Mao… - Frontiers in …, 2024 - frontiersin.org
Esophageal squamous cell carcinoma is a cancer with high morbidity and mortality. The
advent of immune checkpoint inhibitors has significantly increased complete response rates …
advent of immune checkpoint inhibitors has significantly increased complete response rates …
Sitravatinib combined with PD-1 blockade enhances cytotoxic T-cell infiltration by M2 to M1 tumor macrophage repolarization in esophageal adenocarcinoma
R Sweeney, AN Omstead, JT Fitzpatrick… - …, 2024 - academic.oup.com
Esophageal adenocarcinoma (EAC) is a leading cause of cancer-related mortality.
Sitravatinib is a novel multi-gene tyrosine kinase inhibitor (TKI) that targets tumor-associated …
Sitravatinib is a novel multi-gene tyrosine kinase inhibitor (TKI) that targets tumor-associated …